US5648098A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Thrombolytic agents and methods of treatment for thrombosis
Assignee: University of Nebraska System
•
Filing: 1995-10-17
•
Granted: 1997-07-15
•
Expires: 2015-10-17
Abstract
Abstract The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.
Inventors
- 👤 Thomas R. Porter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 15:14
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0028; A61K31/00; A61K31/02; A61K9/00; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5052
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
79 words
A method of treating thrombosis in animals comprising the steps of: introducing a solution consisting essentially of a mixture of dextrose and albumin to said animal by intravenous injection near a thrombus site and thereafter applying ultrasound to said site, said dextrose and albumin mixture comprising a plurality of microbubbles with a diameter of from about 0.1 to 10 microns, said microbubbles having a protein coated shell and an internal atmosphere comprising a gas which is insoluble in blood.
Claim 2
Independent Claim
79 words
A method of treating thrombosis in animals comprising the steps of: introducing a solution consisting essentially of a mixture of dextrose and albumin to said animal by intravenous injection near a thrombus site and thereafter applying ultrasound to said site, said dextrose and albumin mixture comprising a plurality of microbubbles with a diameter of from about 0.1 to 10 microns, said microbubbles having a protein coated shell and an internal atmosphere comprising a gas which is insoluble in blood.
Claim 3
Dependent Claim
16 words
The method of claim 1 wherein said dextrose and albumin mixture is a solution of dextrose.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein said protein coated shell is an albumin coated shell.
Claim 5
Dependent Claim
22 words
The method of claim 1 wherein said insoluble gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluoropentane.
Claim 6
Dependent Claim
12 words
The pharmaceutical composition of claim 4 wherein said perfluorocarbon gas is perfluorobutane.
Claim 7
Dependent Claim
12 words
The pharmaceutical composition is claim 4 wherein said perfluorocarbon gas is perfluoropropane.
Claim 8
Dependent Claim
73 words
The method of claim 1 wherein said pharmaceutical compositions are created by the following steps: mixing an aqueous solution comprising 2% to about 10% by weight of human serum albumin diluted about two fold to about eight fold with 5% to 50% by weight dextrose; and exposing said solution to a sonication horn to create cavitation at particulate sites in said solution generating stable microspheres from about 0.1 to 10 microns in diameter.
Claim 9
Dependent Claim
16 words
The method of claim 7 wherein said dilution of albumin with dextrose is a 3-fold dilution.
Claim 10
Dependent Claim
17 words
The pharmaceutical composition of claim 7 wherein said human serum albumin is a 5% by weight solution.
Claim 11
Dependent Claim
14 words
The method of claim 7 wherein said dextrose is a 5% by weight solution.
Claim 12
Independent Claim
116 words
A method for treating thrombosis in animals comprising: (a) obtaining a pharmaceutical composition which consists essentially of: (i) an aqueous albumin-dextrose solution containing between about a two fold and about an eight fold dilution of between about 5% to 50% by weight dextrose and between about 2% to about 10% by weight human serum albumin; and (ii) microbubbles, having a protein coated shell and a gaseous content of which contain an amount of perfluorocarbon gas effective for achieving a stable concentration of about 5×10 8 microspheres per ml; (b) introducing said pharmaceutical composition to said thrombus; and (c) exposing said microbubbles and said thrombus to an ultrasound field for a time sufficient to lyse said thrombus.
Claim 13
Independent Claim
116 words
A method for treating thrombosis in animals comprising: (a) obtaining a pharmaceutical composition which consists essentially of: (i) an aqueous albumin-dextrose solution containing between about a two fold and about an eight fold dilution of between about 5% to 50% by weight dextrose and between about 2% to about 10% by weight human serum albumin; and (ii) microbubbles, having a protein coated shell and a gaseous content of which contain an amount of perfluorocarbon gas effective for achieving a stable concentration of about 5×10 8 microspheres per ml; (b) introducing said pharmaceutical composition to said thrombus; and (c) exposing said microbubbles and said thrombus to an ultrasound field for a time sufficient to lyse said thrombus.
Claim 14
Dependent Claim
19 words
The method of claim 11 wherein said step of introducing said composition to said thrombus is by intravenous injection.
Claim 15
Dependent Claim
12 words
The method of claim 11 wherein said dextrose is a 5% solution.
Claim 16
Dependent Claim
15 words
The method of claim 11 wherein said protein coated shell is an albumin coated shell.
Claim 17
Dependent Claim
22 words
The method of claim 11 wherein said perfluorocarbon gas is selected from the group consisting of perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane and perfluoropentane.
Claim 18
Dependent Claim
12 words
The pharmaceutical agent of claim 15 wherein said perfluorocarbon gas is perfluorobutane.
Claim 19
Dependent Claim
12 words
The pharmaceutical agent is claim 15 wherein said perfluorocarbon gas is perfluoropropane.
Claim 20
Dependent Claim
73 words
The method of claim 11 wherein said pharmaceutical compositions are created by the following steps: mixing an aqueous solution comprising 2% to about 10% by weight of human serum albumin diluted about two fold to about eight fold with 5% to 50% by weight dextrose; and exposing said solution to a sonication horn to create cavitation at particulate sites in said solution generating stable microspheres from about 0.1 to 10 microns in diameter.
Claim 21
Dependent Claim
16 words
The method of claim 18 wherein said dilution of albumin with dextrose is a 3-fold dilution.
Claim 22
Dependent Claim
17 words
The pharmaceutical agent of claim 16 wherein said human serum albumin is a 5% by weight solution.
Claim 23
Dependent Claim
14 words
The method of claim 18 wherein said dextrose is a 5% by weight solution.
Claim 24
Independent Claim
56 words
A method of treating thrombosis in animals comprising the steps of: introducing a solution of protein encapsulated, blood insoluble gas filled microbubbles to said animal by intravenous injection near a thrombus site, said solution comprising dextrose, albumin and a medicament wherein said medicament is other than a thrombolytic agent, and thereafter applying ultrasound to said site.
Claim 25
Independent Claim
56 words
A method of treating thrombosis in animals comprising the steps of: introducing a solution of protein encapsulated, blood insoluble gas filled microbubbles to said animal by intravenous injection near a thrombus site, said solution comprising dextrose, albumin and a medicament wherein said medicament is other than a thrombolytic agent, and thereafter applying ultrasound to said site.
References Cited (Backward Citations)
US5040537A
Cited
US5310540A
Cited
US5315998A
Cited
US5393524A
Cited
US5409688A
Cited
US5413774A
Cited
US5385725A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-07-14 | 2001-01-13 | 2001-07-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-07-14 | 2005-01-13 | 2005-07-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-07-14 | 2009-01-13 | 2009-07-15 | $7700.00 | Window Closed / Lapsed |